[Genetic Counselor]

Yes, Non-Invasive Prenatal Testing can be done in a twin pregnancy, and it is the most accurate screening test available for Down syndrome in twins. Major professional bodies, including the American College of Obstetricians and Gynecologists and the International Society for Prenatal Diagnosis, recognize it as an option for screening twin pregnancies for the common chromosome conditions.

How the test works

Non-Invasive Prenatal Testing is a simple blood test taken from the mother, usually from about 10 weeks of pregnancy. It looks at small fragments of DNA floating in the mother’s blood. Some of these fragments come from the placenta, which usually reflects the baby’s DNA. The test checks whether there is too much or too little DNA from a particular chromosome.

How accurate it is in twins

For Down syndrome (trisomy 21), a pooled analysis of twin studies found the test picked up about 98 percent of affected pregnancies, with very few false alarms. This is close to its performance in single pregnancies.
For Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13), there is much less information in twins, because these conditions are rare and fewer twin cases have been studied.

What it cannot tell you

This is where twins differ most from single pregnancies:

It usually cannot say which baby is affected. In non-identical twins, a high-risk result means one baby or both may be affected. Only a diagnostic test of each baby can answer that.
Not every test method can tell identical from non-identical twins. Some laboratory methods can estimate this. Others give one combined result for the whole pregnancy.
Some conditions are not reliably screened in twins. Screening for small missing pieces of chromosomes (microdeletions) and for sex chromosome conditions is generally less reliable, or not offered, in twin pregnancies.
It does not check how the babies are developing physically. Problems such as spina bifida or heart defects are picked up on scans, not on this blood test.

Why some twin tests come back with “no result”

The test needs enough placental DNA in the mother’s blood. This is called the fetal fraction. In non-identical twins, each baby contributes only part of the total. One baby’s share can be too low to analyze reliably, even when the overall amount looks fine.

For this reason, “no result” reports are more common in twins. A no-result report does not mean something is wrong. Often, a repeat blood sample a little later in pregnancy solves the problem, and Team Genetidoc offers a repeat sample when the fetal fraction is too low.

Other practical points

Results are usually available in about two weeks.
Genetidoc does not report the sex of the babies, in line with India’s Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994.
A low-risk result greatly lowers the chance of the conditions tested, but it is not a guarantee of healthy babies. Your regular pregnancy scans remain essential.

Genetic counseling before the test helps you understand what a result can and cannot tell you about each baby, so that a report never comes as a shock.

[Genetic Counselor]

You can, but the result needs careful interpretation, and your care team must know about the vanishing twin before the test is done.

What a vanishing twin is

Sometimes an early scan shows two pregnancy sacs, but one baby stops growing within the first few weeks. Doctors call this a vanishing twin. It is more common than many people realize.

It is seen more often in pregnancies conceived through in vitro fertilization, because very early scans are routine in that setting. In most cases, the surviving baby continues to grow normally.

Why it affects Non-Invasive Prenatal Testing

Non-Invasive Prenatal Testing reads small fragments of placental DNA in the mother’s blood. Even after the lost twin stops developing, its placental tissue can keep releasing DNA into the mother’s bloodstream for some time.

Pregnancy losses this early are often caused by a chromosome condition in that baby. If so, the test may pick up the lost twin’s DNA and report a high risk, even though the surviving baby is healthy.

How long this effect lasts

Published reports show the leftover DNA can persist for several weeks. In one documented case, it was still present nine weeks after the loss. Researchers have not agreed on a waiting period after which the test becomes fully reliable. This is why no one can promise that waiting a fixed number of weeks will remove the problem.

What a sensible plan looks like

Team Genetidoc covers a vanishing twin history in counseling before the test. A typical approach includes:

A careful first-trimester scan. The nuchal translucency measurement and early anatomy check of the surviving baby give information about that baby alone, unaffected by the lost twin’s DNA.
An honest discussion of what a result could mean. If you go ahead with Non-Invasive Prenatal Testing, you should know in advance that a high-risk result might come from the lost twin.
Confirmation before any decision. Any high-risk result should be checked with a diagnostic test of the surviving baby, such as amniocentesis, before any decision is made about the pregnancy.

An illustrative example (composite, details changed)

A 34-year-old woman conceived through in vitro fertilization. Her 7-week scan showed two sacs, but by 9 weeks only one baby was growing. At 11 weeks, she asked about Non-Invasive Prenatal Testing.

During counseling, she learned that DNA from the lost twin could still be in her blood. Together with the genetic team, she agreed on a plan: a careful first-trimester scan, and diagnostic testing to confirm any high-risk result before acting on it. Knowing this in advance meant that a confusing report would not catch her off guard.

What you should do

Tell your doctor and the laboratory about any second sac that stopped growing, even if it seemed minor at the time.
Keep your early scan reports, because the timing of the loss helps with interpretation.
Do not make any decision based on a screening result alone.

[Genetic Counselor]

Yes. Prenatal screening or diagnostic testing is still recommended, even if your embryos were tested before transfer. Many couples are surprised by this, especially after a long fertility journey, so it helps to understand why.

What embryo testing actually checks

Preimplantation genetic testing for aneuploidy is the test that checks embryos for an abnormal number of chromosomes before transfer. It looks at a few cells taken from the outer layer of the embryo. These outer cells go on to form the placenta, not the baby itself.

Sometimes the cells that were tested do not perfectly represent the rest of the embryo. This is called mosaicism, where an embryo contains a mixture of cells with different chromosome patterns.

For this reason, embryo testing is considered a screening step, not a final diagnosis. The American College of Obstetricians and Gynecologists recommends that prenatal screening or diagnostic testing still be offered during pregnancy after embryo testing.

Why twin pregnancies after in vitro fertilization need extra care

Identical twins can still happen. Even when only one embryo is transferred, that embryo can split into identical twins. The type of twins, and whether they share a placenta, should be confirmed on the early scan.

A vanishing twin is more often detected. Very early scans are routine after in vitro fertilization, so a second sac that stops growing is more often seen. A lost twin can affect Non-Invasive Prenatal Testing results for several weeks, and your care team needs to know about it.
The double marker test can be affected. Pregnancies conceived through in vitro fertilization can change the levels of the blood markers used in this test. The risk calculation should take the method of conception into account, along with twin-specific adjustment.
Donor eggs need special consideration. Some Non-Invasive Prenatal Testing methods cannot be used in donor-egg pregnancies, particularly with twins. Always tell your doctor and the laboratory if a donor egg was used.

What screening still adds

Prenatal screening is not about doubting your fertility team’s work. It adds information that embryo testing cannot provide:

It reflects the pregnancy as it is now, not a few cells from an earlier stage.
The first-trimester scan measures nuchal translucency and checks early anatomy for each baby.
The anomaly scan at 18 to 22 weeks checks each baby’s organs and body structure, which no genetic test can do.

The emotional side

Couples who have waited years for an in vitro fertilization pregnancy often feel they cannot afford a single wrong step. Some worry that further testing is unnecessary or risky. Others feel anxious about every result.

Genetic counseling helps you choose a screening plan that fits your pregnancy and your values. It also helps you understand what each result does and does not mean.

Practical steps

Bring your embryo testing reports and your fertility clinic records to your counseling session.
Mention whether one or two embryos were transferred and whether a donor egg was used.
Make sure the number of placentas is recorded on your scan before 14 weeks.

Screening is always a choice, never an obligation. But it remains a valuable part of care, even after embryo testing.

[Genetic Counselor]

First, take a breath. A high-risk screening result does not mean your babies definitely have a condition. It means further testing is recommended to find out.

Two of the most common misunderstandings Team Genetidoc sees in prenatal screening are treating a screening result as a diagnosis, and assuming a high-risk result is a confirmed problem. Both can cause unnecessary distress and rushed decisions.

Step one: genetic counseling

A genetic counselor and clinical geneticist will review your result alongside your scans, your twin type and your history. They will explain what the result means for each baby, whether anything such as a vanishing twin could explain it, and what your options are. Bring all your scan reports and blood test reports to this session.

Step two: diagnostic testing, if you choose it

Diagnostic tests examine cells from the pregnancy directly and can confirm or rule out a chromosome condition.

Chorionic villus sampling takes a small sample of placental tissue, usually between 11 and 14 weeks.
Amniocentesis takes a small sample of the fluid around the baby, usually from 15 or 16 weeks.

The cells are then studied with one of two tests. Karyotyping gives a picture of all the chromosomes. Chromosomal microarray analysis is a more detailed test that can find smaller missing or extra pieces of chromosomes.

How this works with twins

Twins with two placentas: each baby is usually sampled separately. The specialist carefully maps which sample came from which baby, so that results can be matched to the right twin.
Twins sharing one placenta: one sample is often enough when the babies look alike on scan, because they are almost always genetically identical. If one baby shows a problem on scan and the other does not, both may be sampled.

The risk of pregnancy loss after these procedures is slightly higher in twins than in single pregnancies. They should be done by a fetal medicine specialist experienced with twins.

Genetidoc does not perform these procedures itself. The team works alongside your obstetrician or fetal medicine specialist to choose the right laboratory test and interpret the results with you.

An illustrative example (composite, details changed)

A couple expecting twins who shared one placenta received a high-risk Non-Invasive Prenatal Testing result for Down syndrome. They assumed only one baby might be affected.

In counseling, they learned that twins sharing a placenta are almost always identical, so the result most likely applied to both. Amniocentesis confirmed the result, and the genetic team explained what it meant for each baby and the support available.

If only one twin is affected

In non-identical twins, one baby can have a chromosome condition while the other is healthy. This is one of the hardest situations a family can face.

Options may include continuing the pregnancy with additional planning and support, or, in some situations, a procedure called selective reduction. Whether this is possible, and how safe it is for the healthy twin, depends on whether the twins share a placenta and on the stage of pregnancy. These procedures are done only at specialized fetal medicine centres, and Indian law sets time limits and conditions that your fetal medicine team will explain.

[Genetic Counselor]

Screening for Cowden syndrome is intended to find certain cancers or concerning changes early, when they may be easier to manage. The plan is tailored to the person’s age, health, family history, and previous findings. Recommendations differ somewhat across guidelines, so screening ages should be confirmed with the clinician or genetics team overseeing care.

Depending on the guidance followed, monitoring may include thyroid ultrasound and clinical examination. Recommendations for when to begin ultrasound in children vary: some guidelines start at age 7, while the current GeneReviews schedule lists age 12. This difference is one reason to get an individualized plan rather than relying on a general online schedule. If a thyroid nodule is already known, the clinician may recommend a different approach.

For women with PHTS, breast surveillance may include breast MRI and mammography, often beginning around age 30 to 35 in some guidance. Other recommendations begin MRI earlier. The schedule may be adjusted when a close relative developed breast cancer at a young age. A high-risk breast clinic can discuss screening choices and how to balance the benefits and burdens of each option.
Colonoscopy is commonly recommended from around age 35, with the timing and repeat interval adjusted for symptoms, family history, and the number or type of polyps found. Kidney imaging may be considered from around age 40, though some guidance begins in the mid-to-late 30s. Skin checks and education about possible melanoma symptoms may also be included.

For endometrial cancer, a key part of care is knowing to seek medical advice for abnormal or unexpected vaginal bleeding. Some guidelines do not recommend routine screening for people without symptoms, while others discuss additional monitoring in selected circumstances. A clinician can explain the approach appropriate to the person.

Screening plans can change as a person gets older or as new findings and updated guidance become available. Family history may lead a clinician to recommend starting some checks earlier. Screening is not a guarantee that cancer will be prevented or found, and no single schedule fits everyone. It is best to keep a written plan listing which checks are due and when, and to contact the care team if symptoms arise between appointments.

[Genetic Counselor]

Testing for inherited Cowden syndrome looks for a harmful PTEN variant in a person’s germline DNA—the DNA present in most of their body’s cells and potentially passed to their children. Testing is often done using a blood or saliva sample. A clinician may order a test focused on PTEN or a broader genetic panel, depending on the person’s features and family history.

A result showing a harmful inherited PTEN variant can help confirm PHTS and guide medical care. It may also allow relatives to have targeted testing for the specific variant found in the family. A result that does not find a variant does not always explain every symptom or rule out a clinical diagnosis. The meaning depends on the test performed and the person’s history, so a clinical geneticist or genetic counselor should interpret it.

A PTEN change found by tumor testing is a different kind of result. Tumor testing examines DNA in cancer tissue, often to help guide treatment. Some changes arise only in the tumor during a person’s lifetime; these are called somatic changes. A somatic PTEN change does not, by itself, show that the person was born with the change or that relatives may have inherited it.

Tumor testing can sometimes detect a change that is also inherited. If a PTEN variant is found in tumor tissue, the treating team may recommend a separate test using blood or saliva to determine whether it is present in the germline. This is especially relevant when the person’s personal or family history suggests PHTS, or when knowing the inherited status could affect care for the person or their relatives.

Testing is most useful when it is chosen and interpreted with medical context. A genetic professional can review the person’s history, explain what the test can and cannot detect, and discuss possible results. These may include a harmful variant, no variant detected, or a variant of uncertain significance—a change for which there is not enough evidence to know whether it affects health. A variant of uncertain significance generally should not be treated as a confirmed diagnosis without further evidence.

If you are in India, the same basic distinction applies: ask whether the proposed test checks for an inherited variant in blood or saliva, or only analyzes tumor tissue. The laboratory’s turnaround time varies, so confirm it directly with the testing provider.

[Genetic Counselor]

Cowden syndrome is linked to an increased risk of several cancers. It is part of PTEN hamartoma tumor syndrome (PHTS), which can involve increased risks of breast, thyroid, endometrial, kidney, and colorectal cancer. Some studies also suggest a possible increase in melanoma risk. These are increased risks, not certainties: having a PTEN variant does not mean a person will develop cancer.
For women with PHTS, breast cancer is a major concern. Published estimates differ because studies have included different groups of patients and used different methods. One analysis that accounted for study bias estimated a risk of roughly 54% to 76% by age 60. Those figures describe groups, not an individual’s exact likelihood. Personal and family history, age, and other factors can affect a person’s risk assessment.

Thyroid cancer risk is also elevated. Follicular thyroid cancer is more common in PHTS than it is in the general population, although other types can occur. People may also develop benign thyroid nodules or goiter. Because thyroid changes can be benign or malignant, any monitoring plan should be based on medical guidance rather than on symptoms alone.
Endometrial cancer affects the lining of the uterus. People should know to report symptoms such as unexpected or abnormal vaginal bleeding promptly. Routine screening approaches are not identical across guidelines, so a clinician can explain whether any monitoring is appropriate for a particular person.

There are increased risks of kidney and colorectal cancer as well. Colorectal polyps can occur in PHTS, and colonoscopy may be recommended to assess polyps and detect concerning changes. Kidney imaging may also be considered as part of a surveillance plan. Skin examinations may be useful because melanoma risk may be increased.

These risks are why care often includes a tailored screening schedule and education about symptoms that warrant medical assessment. Recommendations can differ by guideline, age, sex, medical history, and family history. For example, if a close relative developed a related cancer at a young age, a clinician may consider starting certain screening earlier.

A clinical geneticist, genetic counselor, or specialist team can explain which risks apply and how current guidance fits the person’s situation. Avoid treating a single lifetime-risk number as a prediction for an individual; it is a planning tool, not a diagnosis or forecast.

[Genetic Counselor]

Cowden syndrome can affect several parts of the body, and its features vary from person to person. A combination of certain signs may lead a clinician to consider PTEN hamartoma tumor syndrome (PHTS), but none of these signs alone proves that someone has it.
A larger-than-average head size, called macrocephaly, is a common feature. It may be noticed in childhood, sometimes alongside developmental delay, learning differences, or autism. A clinician considers head size in relation to age and other features; head size alone does not establish a diagnosis.

Many people develop skin or mouth growths. These may include small, often skin-colored bumps on the face; smooth or wart-like bumps in the mouth; or rough areas on the hands and feet. Some of these growths are hamartomas, which are noncancerous overgrowths of tissue normally found in that area. They may become more apparent over time. Their appearance can resemble other common skin conditions, so assessment by a clinician familiar with PHTS can be helpful.

Thyroid changes are another possible feature. These include thyroid nodules, goiter (an enlarged thyroid), or other benign thyroid growths. Thyroid nodules are common in the general population too, so their presence does not automatically indicate Cowden syndrome. A clinician will consider the full pattern of signs and family history.

Some people have polyps in the gastrointestinal tract. Polyps are growths on the inner lining of the digestive system. They may be found during an endoscopy or colonoscopy and may be of different types. Their number, type, and symptoms can vary. Abdominal symptoms or a polyp finding should be discussed with a healthcare professional, who can decide whether further assessment is needed.
Features can appear at different ages. Skin and mouth signs often become more noticeable by adulthood, while a large head size or developmental differences may draw attention earlier in childhood. A person may have some features but not others, and relatives with the same PTEN variant can have different experiences.

Doctors assess the whole picture: physical findings, personal medical history, family history of related cancers or features, and genetic test results. If the pattern raises concern, referral to a clinical geneticist or genetic counselor can help determine whether testing is appropriate. A diagnosis should not be made from a list of signs alone.

[Genetic Counselor]

Cowden syndrome is part of a group of conditions called PTEN hamartoma tumor syndrome (PHTS). It is usually caused by a harmful variant—sometimes called a mutation—in one copy of the PTEN gene. The PTEN gene helps regulate cell growth. When it does not work properly, certain cells may grow or form growths more readily. Many of these growths are benign, but the change also raises the chance of developing some cancers.

Cowden syndrome is usually inherited in an autosomal dominant pattern. A person has two copies of most genes, one from each parent. If a person has a harmful PTEN variant in one copy, each of their children has a 50% chance of inheriting that variant. The chance is the same for each pregnancy, and the variant can be passed on by people of any sex.
Sometimes the variant is not inherited from either parent. It can arise for the first time in the affected person; this is called a de novo variant. In that situation, the person may be the first in the family known to have Cowden syndrome. A de novo result does not mean the person did anything to cause it.

An inherited PTEN variant can affect people in the same family differently. One relative may have noticeable skin or mouth growths, while another may have few obvious features. The age when features appear and the types of health problems can also vary. So, a relative who seems healthy may still carry the family variant.

When a harmful inherited variant is found in one person, relatives may be offered genetic counseling and targeted testing for that specific variant. This can help identify who may benefit from screening and who did not inherit the family variant. A genetic counselor or clinical geneticist can explain what a test result means, discuss possible implications for relatives, and help plan next steps.
Cowden syndrome is one condition within the broader PHTS group. People with a harmful inherited PTEN variant can have overlapping features, and their clinical label may depend on their particular symptoms and medical history. In practice, care is guided by the person’s PTEN result, health features, and family history.

[Genetic Counselor]

It is often helpful for close relatives to discuss assessment with a clinical geneticist or genetic counsellor. Marfan syndrome can be inherited, and some people have subtle features or feel well despite having changes that need monitoring. A family member’s diagnosis can therefore be a reason to check whether parents, siblings, or children may also be affected.

If a disease-causing genetic variant has been identified in the family, relatives can be offered a targeted test for that specific variant. This is different from repeating a broad genetic panel: it checks whether the known family change is present. If a relative tests positive, their care team can arrange appropriate heart imaging, eye examinations, and other follow-up. A negative targeted result may mean that the person did not inherit that specific family variant, but the result should still be interpreted by their clinician.

Children may be considered for testing because Marfan syndrome can affect the heart, eyes, and skeleton during childhood. Finding the condition early can help doctors begin monitoring and care when needed. A genetics professional can help the family decide who should be tested, when to do it, and how to talk with children about the result.

[Genetic Counselor]

A negative genetic test means that the laboratory did not find a reportable disease-causing change in the genes examined. It does not always mean that the person does not have Marfan syndrome. Genetic tests can identify many important changes, but they may not detect every possible variant. The result also depends on which genes and types of changes the test was designed to assess.

Doctors interpret the result alongside the person’s physical features, heart and eye examinations, and family history. Marfan syndrome can sometimes be diagnosed using clinical criteria even when testing does not identify a genetic cause. A clinical geneticist may review whether the test was suitable or whether a broader panel or another kind of test could provide more information.

Most importantly, a negative result does not remove the need to care for a medical finding. If someone has a widened aorta, their cardiologist should continue to advise on monitoring and treatment based on the scans and overall health. The doctor can also explain what the result means for relatives.

[Genetic Counselor]

Physical activity can support general health, and many people with Marfan syndrome can exercise. However, the type and intensity of activity matter because some exercises can put excessive strain on the aorta. For some people, moderate activities such as walking, gentle cycling, or relaxed recreational swimming may be suitable. A comfortable pace that allows someone to talk while exercising may be more appropriate than pushing to their limits.

Heavy weightlifting, intense competitive sports, and exercises that involve straining or holding the breath can cause sudden increases in blood pressure. This may place extra stress on the aortic wall. Contact sports may also carry a risk of a blow or injury. These are general considerations, not a personal exercise prescription. What is suitable depends on a person’s aortic measurements, heart health, age, and treatment plan.

Before starting a new sport, joining a gym, or significantly changing an exercise routine, ask a cardiologist for advice. The doctor can explain which activities are appropriate and whether any restrictions are needed. Stop exercising and seek emergency medical care if sudden, severe chest, back, or abdominal pain occurs.

[Genetic Counselor]

Regular check-ups are important because changes linked to Marfan syndrome can develop without obvious symptoms. One of the main concerns is the aorta, the large blood vessel that carries blood away from the heart. In some people, the aorta gradually widens. This usually does not cause pain or make someone feel unwell at first, so imaging is needed to monitor it.

An echocardiogram is an ultrasound scan that lets doctors examine the heart and measure part of the aorta. After diagnosis, a cardiologist may recommend another scan in about six months to check whether the aorta is changing. If it remains stable, scans are often done at least once a year. If it is widening or there are other concerns, scans may be needed more often. A CT or MRI may also be recommended to examine parts of the aorta that an echocardiogram cannot show clearly.

Eye examinations are important as well. An eye specialist can check whether the lens has shifted and look for short-sightedness, retinal problems, glaucoma, or cataracts. The schedule depends on the person’s age and findings. Ask the cardiologist and eye specialist how often check-ups are needed, and keep appointments even when there are no symptoms.

[Genetic Counselor]

Yes. Alpha-thalassemia is inherited in an autosomal recessive pattern, but because four genes are involved, working out the risk for a family is more detailed than for most recessive conditions.
The key question is not only how many genes each parent is missing, but how the missing genes are arranged. Remember that each person carries two chromosome 16 copies, each with two alpha-globin genes. A person with alpha-thalassemia trait is missing two genes, and those two can be arranged in two ways:
• Both missing genes on the same chromosome. One chromosome has no working alpha-globin genes, and the other is normal. This arrangement is called “cis.”
• One missing gene on each chromosome. Each chromosome still has one working gene. This arrangement is called “trans.”
Both arrangements look the same on a blood test, but they carry very different risks for children, because a parent passes on one whole chromosome, not single genes.
When both parents carry the “cis” arrangement, each pregnancy has a 1-in-4 chance of the baby inheriting two empty chromosomes and having hemoglobin Bart’s hydrops fetalis, a 1-in-2 chance of the baby having alpha-thalassemia trait, and a 1-in-4 chance of the baby being unaffected.
When one parent has the “cis” arrangement and the other is a silent carrier or has the “trans” arrangement, each pregnancy has a 1-in-4 chance of hemoglobin H disease. In this situation, hemoglobin Bart’s hydrops fetalis cannot occur, because the second parent always passes on at least one working gene.
When both parents have only single-gene deletions, whether silent carriers or “trans” trait, children cannot have hemoglobin H disease or hydrops from deletions alone.
Only DNA testing can tell which arrangement a person has, which is why couples in whom one partner has small red blood cells should have alpha-globin gene testing, ideally before pregnancy.
Alpha-thalassemia is common in India. Carrier rates range from about 1 to 18 percent in different non-tribal communities and are much higher in some tribal communities. Single-gene deletions are by far the most common type. The “cis” two-gene deletion responsible for hydrops is less common in India than in Southeast Asia, but it does occur, and several different forms of hemoglobin H disease have been reported across at least 13 Indian states.
Alpha-thalassemia can also be inherited alongside beta-thalassemia, and this can change how severe beta-thalassemia is. For couples at risk, options include prenatal diagnosis through chorionic villus sampling or amniocentesis, and preimplantation genetic testing with in vitro fertilization. A genetic counselor can explain what each option means for your family.

[Genetic Counselor]

Silent carriers and people with alpha-thalassemia trait do not need treatment. The main practical point is to avoid iron tablets unless iron deficiency has actually been confirmed by blood tests.

For hemoglobin H disease, many individuals need little treatment, but good everyday care prevents problems:

Folic acid A daily folic acid supplement supports the bone marrow, which works harder than usual to replace red blood cells that break down early.
Avoiding triggers Certain medicines and substances can damage red blood cells and cause a sudden drop in hemoglobin. The list is similar to the one given for glucose-6-phosphate dehydrogenase deficiency, and includes some antibiotics, antimalarial medicines, and mothballs. Always tell doctors and pharmacists about the diagnosis before starting new medicines.
Prompt care for fever and infection Fever is the most common trigger for a hemolytic crisis. Many crises need close monitoring, and some need a blood transfusion.
Blood transfusions Most people with deletion-type hemoglobin H disease only need transfusions during crises, surgery, or pregnancy. Some with more severe forms need regular transfusions.
Iron chelation therapy Even without transfusions, the body absorbs more iron from food in hemoglobin H disease, and iron slowly builds up in the liver and other organs. Iron-removing medicines are started when blood or liver tests show the iron level has become too high.
Removal of the spleen This may be considered when anemia is severe or crises are frequent. It raises the risk of infection and blood clots, so it is weighed carefully, and blood-thinning precautions are used afterwards.
Mitapivat In December 2025, the United States Food and Drug Administration approved this oral medicine for anemia in adults with alpha-thalassemia or beta-thalassemia. It helps red blood cells produce energy and survive longer. It needs regular liver monitoring because of a risk of liver injury, and its availability in India is still limited.

For hemoglobin Bart’s hydrops fetalis, treatment may begin during pregnancy. Blood transfusions given to the baby in the womb, called intrauterine transfusions, can reverse the fluid build-up and allow some babies to survive. After birth, these children need regular transfusions and iron chelation for life, unless they have a hematopoietic stem cell transplant. This transplant replaces the bone marrow with healthy donor stem cells and is currently the only cure. The decision to continue a pregnancy with intrauterine treatment is personal and deserves detailed discussion with a fetal medicine specialist and a genetic counselor, since the baby’s long-term health and the mother’s own health are both involved.

[Author]

Posts